MedGenesis Therapeutix Inc. MedGenesis Therapeutix Inc.
 

Company

[ News ] [ Our People ] [ Awards ]

News

MedGenesis Therapeutix Announces Successful National Scientific Advice Meetings for GDNF in Parkinson's Disease

Victoria BC, 1-Sep-2017

MedGenesis Therapeutix Inc., a privately held biotechnology company focused on the development of glial cell line-derived neurotrophic factor (GDNF), announced today the successful outcome of national scientific advice meetings with three European regulatory agencies including the British Medicines and Healthcare products Regulatory Agency (MHRA), the Dutch Medicines Evaluation Board (MEB), and the German Federal Institute for Drugs and Medical Devices (BfArM). The primary purpose of the meetings was to discuss the design of a proposed Phase 3 study to support registration of GDNF as a disease-modifying therapy for Parkinson's disease.

"The consulted agencies are regulatory leaders in neurodegenerative diseases in the European Union. All three endorsed our proposed Phase 3 study design and strongly encouraged further development of GDNF in Parkinson's disease," said Dr. Erich Mohr, Chairman and CEO of MedGenesis. "The consistent feedback gives us confidence as we next review our strategy with the Scientific Advice Working Party of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). These upcoming meetings are expected to be cornerstones on the way forward to initiating Phase 3."

Dr. Matthias Luz, Chief Medical Officer of MedGenesis added, "Importantly, we are encouraged by the provided guidance that if the proposed study achieves its key endpoints and demonstrates a favorable benefit-risk ratio, it could be the only study required for marketing authorization. We are now focused on preparing for the next stage of regulatory meetings and finalizing the Phase 3 study design."

MedGenesis' proposed target population for its Phase 3 study of GDNF is patients with bilateral idiopathic Parkinson's disease of moderate severity. Details of the study design will be announced following the completion of discussions with the EMA and FDA.

About MedGenesis Therapeutix Inc.

MedGenesis is a privately held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis' GDNF program has been supported by a grant from the Michael J Fox Foundation for Parkinson's Research, and benefitted from a direct grant from Parkinson's UK to an investigator-sponsored clinical trial conducted by the North Bristol Trust.

Learn more about MedGenesis at: www.medgenesis.com

FOR FURTHER INFORMATION PLEASE CONTACT:
MedGenesis Therapeutix Inc.:
Lara Longpre, M.Sc., MBA
Chief Operating Officer
+1 (250) 386-3000

This news release contains certain forward looking statements that reflect the current views and/or expectations of the company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


Parkinson's UK & MedGenesis Therapeutix Inc. announce top-line results of Phase 2 GDNF safety and efficacy clinical trial

London, 7-Jul-2016

Parkinson's UK and MedGenesis Therapeutix Inc. announced today that the Phase 2 clinical trial evaluating the safety and efficacy of glial cell line-derived neurotrophic factor (GDNF) in Parkinson's disease, delivered via intermittent bilateral intraputamenal infusions using convection enhanced delivery (CED) and conducted at Southmead Hospital by the North Bristol NHS Trust, did not meet the primary efficacy endpoint. Show More

The primary endpoint of the study is the percentage change from baseline in the practically defined OFF-state Unified Parkinson's Disease Rating Scale (UPDRS) motor score (part III) after nine months of double-blind treatment.

The study was funded by Parkinson's UK, with support from The Cure Parkinson's Trust and in association with the North Bristol NHS Trust. Study drug, additional project resources and supplementary funding was provided by MedGenesis Therapeutix, who in turn received some program funding support from the Michael J. Fox Foundation for Parkinson's Research. Renishaw plc manufactured the CED device on behalf of the North Bristol NHS trust and provided additional technical and analytical support. PET scans were acquired at the Wales Research and Diagnostic PET Imaging Centre, Cardiff University and analysed at the PET Imaging Centre at the University of British Columbia. Most importantly, the researchers would like to gratefully acknowledge the contribution of the study participants.

ENDS

Media enquiries

Please contact: Hanna Kilpin, Parkinson's UK Senior Media & PR Officer on +44 20 7963 9311 or email: hkilpin@parkinsons.org.uk

Out of hours: +44 7961 460248

Notes to editors:

About GDNF

GDNF is the major neurotrophic factor for dopamine neurons and has an impact on several other relevant neurotransmitter systems. It has established disease-modifying efficacy in all key animal models of Parkinson's disease, having displayed neuroprotection, axonal sprouting, and improved motor function in preclinical research. Previous clinical trials include two open-label Phase I studies (n=15) with positive results that were sustained well beyond the end of treatment, and a placebo-controlled Phase II study (n=34) that did not confirm efficacy. The results of this Phase II study are likely to have been the result of poor delivery of the drug to the target tissue in the putamen, due to the immature state of CED expertise and limited technology available at that time to provide for accurate, precise and verified distribution of the therapeutic agent across a therapeutically relevant fraction of the target structure within the brain. On the basis of the available preclinical and clinical evidence, GDNF offers the potential for the first ever disease-modifying treatment of Parkinson's disease.

About Parkinson's UK

Every hour, someone in the UK is told they have Parkinson's.

It affects 127,000 people in the UK - which is around one in 500 of the population.

Parkinson's is a degenerative neurological condition, for which there currently is no cure. The main symptoms of the condition are tremor, slowness of movement and rigidity.

Parkinson's UK is the UK's leading charity supporting those with the condition. Its mission is to find a cure and improve life for everyone affected by Parkinson's through cutting edge research, information, support and campaigning.

For advice, information and support, visit www.parkinsons.org.uk or call our free, confidential helpline on 0808 800 0303.

About MedGenesis Therapeutix Inc.

MedGenesis is a privately held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases, employing convection-enhanced delivery (CED), a minimally invasive technique that provides for targeted, local treatment of serious conditions such as Parkinson's, epilepsy, brain cancer and other severely debilitating diseases of the central nervous system.

Learn more about MedGenesis at: www.medgenesis.com

Show Less

 


MedGenesis Enters Into Agreement with Pfizer Inc. for Potential Treatments for Parkinson's Disease

Victoria BC, 16-Sep-2014

MedGenesis Therapeutix Inc. ("MedGenesis"), a privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, announced today that it has entered into an agreement with Pfizer Inc. ("Pfizer"), granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease. Show More

Dr. Erich Mohr, Chief Executive Officer and Chairman of MedGenesis commented, "We believe that delivering drugs, including proteins, precisely to the regions of the brain where they are required will allow the potential for better treatments for a whole range of central nervous system (CNS) disease, and opens up the opportunity for the potential development of truly disease-modifying treatments of neurological diseases. We are delighted to be collaborating with Pfizer to complete our GDNF program, and we hope that this collaboration will result in potential treatments for people living with Parkinson's that could radically alter the course of their disease."

MedGenesis is currently running a proof of concept study in Parkinson's disease with its aforementioned GDNF and CED technology. Under the terms of the agreement MedGenesis will receive an upfront option fee and upon exercise of the option by Pfizer will be eligible for further milestone and royalty payments.

"Pfizer is committed to improving the lives of people living with neurological diseases, including Parkinson's disease," said Michael Ehlers, Senior Vice President, Neuroscience Research Unit, Pfizer. "With limited treatment options currently available, Parkinson's disease is a devastating illness for patients and families. We believe that this collaboration with MedGenesis has the potential to provide the first disease-modifying treatment that slows the progressive decline in patients, consistent with our commitment to making a difference in areas of high unmet medical need."

About MedGenesis Therapeutix Inc.

MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in convection-enhanced delivery (CED), a minimally invasive technique that provides for targeted, local treatment of serious conditions such as Parkinson's, epilepsy, brain cancer and other severely debilitating diseases of the central nervous system. MedGenesis' GDNF program has been supported by a grant from the Michael J Fox Foundation for Parkinson's Research, and benefitted from a direct grant from Parkinson's UK to an investigator-sponsored clinical trial being conducted by the North Bristol Trust.

Learn more about MedGenesis at: www.medgenesis.com

FOR FURTHER INFORMATION PLEASE CONTACT:

MedGenesis Therapeutix Inc.:
Greg A. Johnson
President and CFO
+1 (250) 386-3000
 

This news release contains certain forward looking statements that reflect the current views and/or expectations of the company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Show Less

 


MedGenesis Announces New Grant for the Development of GDNF

Victoria BC, 9-Oct-2012

MedGenesis Therapeutix Inc, a privately held biotechnology company focused on the development of definitive treatments for neurologic diseases, today announced that the Deutsche Parkinson Vereinigung e.V. has awarded a substantial grant to MedGenesis to support the Phase II development of glial cell line derived neurotrophic factor (GDNF). Show More

"We are deeply appreciative to the Deutsche Parkinson Vereinigung for joining the alliance in support of our GDNF program in Parkinson's disease" said Dr. Erich Mohr, Chairman and CEO of MedGenesis. "GDNF has the potential to become the first disease-modifying treatment in Parkinson's disease and could significantly change the quality of life of the affected patients."

"On behalf of our association and all those patients suffering from Parkinson's disease, we are pleased to have the opportunity to support this program that may have a distinct impact on the disease and gives reason for hope to many patients," said Friedrich-Wilhelm Mehrhoff, Managing Director of the Deutsche Parkinson Vereinigung e.V.

About MedGenesis Therapeutix Inc.

MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in convection-enhanced delivery (CED), a minimally invasive technique that provides for targeted, local treatment of serious conditions such as Parkinson's disease, epilepsy, brain cancer and other severely debilitating diseases of the central nervous system.

Learn more about MedGenesis at: www.medgenesis.com

About Deutsche Parkinson Vereinigung e.V.

The Deutsche Parkinson Vereinigung is a self-help organization that was founded in 1981 by people affected by Parkinson's disease. Today, the association has approximately 23,000 members and more than 450 regional groups and contact points. The aim of the Deutsche Parkinson Vereinigung is to improve the lives of Parkinson's patients and their partners. To that end, the association is committed to actively support research into new therapies and treatment approaches for Parkinson's disease. Another key concern is to provide patients with relevant information and strengthen their self-confidence to make them informed partners in the therapeutic alliance with their doctors and caregivers.

Learn more about Deutsche Parkinson Vereinigung e.V at: http://www.parkinson-vereinigung.de/

FOR FURTHER INFORMATION PLEASE CONTACT:

MedGenesis Therapeutix Inc.:

Greg A. Johnson
President and CFO
+1 (250) 386-3000, ext 226

Deutsche Parkinson Vereinigung e.V:

Friedrich-Wilhelm Mehrhoff
Managing Director
+49 (2131) 740-270

This news release contains certain forward looking statements that reflect the current views and/or expectations of the company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Show Less

 


MedGenesis Therapeutix raises $5.0 million in equity financing to support the Phase II development of GDNF in Parkinson's Disease

Victoria BC, 10-Jan-2012

MedGenesis Therapeutix Inc, a privately held biotechnology company focused on the development of definitive treatments for neurologic disease, announced today that it has raised $5.0 million to support the phase II clinical development of glial cell derived neurotrophic factor protein (GDNF) in Parkinson's disease. GDNF is a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine producing nerve cells. Show More

"This financing will assist us in the completion of the phase II clinical program for GDNF and allows us to now shift our focus to financing our Phase III program, including the development of pharmaceutical company partnerships" said Dr. Erich Mohr, Chairman and CEO of MedGenesis Therapeutix. "We are hopeful that this potentially disease-modifying treatment will significantly change the quality of life of patients with Parkinson's disease as well as have applications in other neurological indications."

Parkinson's disease is a progressive and debilitating neurological disease affecting more than 5 million people worldwide.

About MedGenesis Therapeutix Inc.

MedGenesis Therapeutix is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis Therapeutix is a worldwide leader in Convection Enhanced Delivery (CED), a minimally invasive technique that provides for targeted, local treatment of CNS conditions such as Parkinson's Disease, Epilepsy, Brain Cancer and other severely debilitating diseases of the CNS.

Learn more about MedGenesis Therapeutix at: www.medgenesis.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Michael Lincoln
Chief Financial Officer
(250) 386-3000, ext 227

Show Less

 


MedGenesis Therapeutix Selects SynapCell for Key Preclinical Epilepsy Research

19-Apr-2011

MedGenesis Therapeutix Inc., which develops and commercializes innovative treatments for patients with serious neurological diseases, has selected SynapCell to provide preclinical proof of concept for its lead product, GDNF, in chronic epilepsy. Show More

Grenoble, France-based biotechnology firm SynapCell, which provides preclinical research on treatments for epilepsy, announced today the signing of a preclinical epilepsy research agreement with MedGenesis Therapeutix Inc.

The research will employ a new relevant model of chronic epilepsy to test MedGenesis Therapeutix's lead product, GDNF, in combination with the company’s proprietary Convection Enhanced Delivery (CED) technology.

"We were seeking a partner capable of effectively testing GDNF in a relevant epilepsy model using our CED technology for targeted delivery of the drug to the epileptic foci in the brain without systemic exposure. Of the companies we were looking at, SynapCell was the only one to possess the necessary know-how in two fields: epilepsy models and intracerebral injection. We hope that the disease-modifying potential of GDNF which has been demonstrated in Parkinson's disease already will now also be demonstrated in epilepsy and help improve the lives of epilepsy patients," said MedGenesis Chairman and CEO Dr. Erich Mohr.

"This project falls within the scope of SynapCell's core business: assessing the efficacy of epilepsy treatments. However, our partnership with MedGenesis takes things a step further. We drew upon our in-depth knowledge of epilepsy models for proof-of-concept testing in an entirely new model of temporal lobe epilepsy that we have successfully implemented. We are now moving ahead with the actual research, which will go on for nine months. Our final report will provide a detailed review of the effects of GDNF on the frequency and intensity of behavioral and electroencephalographic seizures, and its potential to reverse the typical neurodegenerative changes seen with the disease," said SynapCell CEO Dr. Corinne Roucard.

SynapCell will be presenting its chronic animal models of epilepsy during the 11th Antiepileptic Drug Trials Conference that will be hold in Florida, 27-29 April 2011.

About SynapCell

SynapCell is a biotechnology firm specializing in epilepsy, providing the biopharmaceutical industry with innovative preclinical solutions to assess drug efficacy and identify side effects. SynapCell possesses a level of scientific expertise that is unique on the market. The company has developed predictive biological models for human diseases, offers recognized neurosurgical expertise, and uses powerful tools to test the electrical activity of neural networks.

Learn more about SynapCell at: www.synapcell.com

About MedGenesis Therapeutix Inc.

MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in Convection Enhanced Delivery (CED), a minimally invasive technique that provides for targeted, local treatment of CNS conditions such as epilepsy, brain cancer and other severely debilitating diseases of the CNS.

Learn more about MedGenesis Therapeutix at: www.medgenesis.com

Press Contact

SynapCell - Corinne Roucard - PhD, CEO
Tel.: +33 4 76 63 75 90
Email: contact@synapcell.com

Show Less

 


MedGenesis Therapeutix Reacquires Rights for GDNF

8-Nov-2010

MedGenesis Therapeutix Inc. ("MedGenesis"), announced today that it has regained all rights to glial cell line-derived neurotrophic factor (GDNF) protein and related Convection Enhanced Delivery (CED) technology from Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE and TSX: VRX). Show More

MedGenesis and BLS agreed to conclude their previously established collaboration to develop and commercialize GDNF, returning the product to MedGenesis together with a one-time cash payment of $5 million to accelerate the development of GDNF in Parkinson’s disease. At the same time, MedGenesis has broadened GDNF applications to hearing loss and epilepsy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Michael Lincoln
Chief Financial Officer
(250) 386-3000

Show Less

 


MedGenesis and Biovail Announce Grant from The Michael J. Fox Foundation for the Development of GDNF

22-Jun-2010

MedGenesis Therapeutix Inc. and Biovail Corporation (NYSE, TSX: BVF) today announced that The Michael J. Fox Foundation (MJFF) for Parkinson's Research has awarded a $2.1 million USD grant to MedGenesis Therapeutix Inc. and Biovail Laboratories International SRL (BLS) to further their collaboration in the development of glial cell line derived neurotrophic factor (GDNF). Show More

The grant will be made over a 3-year period; with the total amount being subject to the attainment of specific milestones.

"We are delighted and deeply appreciative to partner with The Michael J. Fox Foundation in our common search for a disease-modifying treatment to significantly change the quality of life of patients with Parkinson's disease," said Dr. Erich Mohr, Chairman and CEO of MedGenesis.

GDNF is being developed by MedGenesis and BLS pursuant to a December 2009 collaboration agreement. In previous clinical studies, GDNF has shown promise as a potential disease-modifying therapy for the treatment of Parkinson's disease. GDNF is a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine producing nerve cells.

"We are grateful for MJFF's support and look forward to a productive relationship in the future," said Bill Wells, Biovail's Chief Executive Officer.

About MedGenesis Therapeutix Inc.

MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in Convection Enhanced Delivery (CED), a minimally invasive technique that provides for targeted, local treatment of CNS conditions such as epilepsy, brain cancer and other severely debilitating diseases of the CNS.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company’s Web site at www.biovail.com.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson’s disease through an aggressively funded research agenda. MJFF has funded almost $184 million in research to date.

Caution Regarding Forward-Looking Information and "Safe Harbor" Statement

To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information under applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, Biovail's and MedGenesis’ objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can generally be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may", "potential" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

Although Biovail and MedGenesis believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties with respect to the development path that will be required by regulatory authorities, uncertainties associated with the launch of a new product and the accuracy of associated research, availability of raw materials and finished products, the regulatory environment and associated filings and approvals, and other risks detailed from time to time in Biovail's filings with the Securities and Exchange Commission and the Canadian Securities Administrators, as well as the ability of Biovail and MedGenesis to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading "Risk Factors" in Biovail's most recent Annual Report on Form 10-K.

Biovail and MedGenesis caution that the foregoing list of important factors that may affect future results is not exhaustive. When relying on these forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Biovail and MedGenesis undertake no obligation to update or revise any forward-looking statement, except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

Michael Lincoln
Chief Financial Officer
(250) 386-3000

Show Less

 


MedGenesis Announces Agreements with Amgen and Biovail

12-Jan-2010

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. (Nasdaq:AMGN) ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below. Show More

As part of the license agreement, Amgen now holds a small equity stake in MedGenesis. In parallel, Biovail Laboratories International SRL, a subsidiary of Biovail Corporation (NYSE:BVF) (TSX:BVF), Canada's largest publicly traded pharmaceutical company, and MedGenesis have concluded an agreement to collaborate on the development of GDNF in Parkinson's disease and potentially other CNS indications. Biovail, which is also a party to the Amgen license for CNS indications and which has a co-exclusive license to exploit GDNF in certain countries (including the U.S., Canada, Japan and a number of European countries), contributes significant development expertise, a broad-based commercialization track record, and a focus on CNS disorders.

MedGenesis has also granted Biovail a license to its Convection Enhanced Delivery (CED) platform for use with GDNF in CNS indications. MedGenesis and Biovail will initially focus on the development of GDNF for Parkinson's disease, a progressive and debilitating neurological disease affecting close to 5 million patients worldwide. GDNF is a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine producing nerve cells.

"This license of GDNF from Amgen presents MedGenesis and Biovail with an exciting opportunity to develop a potential breakthrough therapy for the treatment of patients with Parkinson's disease. We believe that our Convection Enhanced Delivery approach will result in accurate, targeted delivery of GDNF to the regions of the brain affected by this severely debilitating disease and holds the promise of providing patients for the first time with a treatment which could potentially modify the disease, rather than just treat the symptoms," said Dr. Erich Mohr, Chairman and CEO of MedGenesis. "We are also excited to have licensed the GDNF protein exclusively from Amgen in non-CNS indications and to have the opportunity to investigate additional applications of the molecule through similar collaborations with other potential partners."

About MedGenesis Therapeutix Inc.

MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in CED, a minimally invasive technique that provides for targeted, local treatment of CNS conditions such as epilepsy, brain cancer and other severely debilitating diseases of the CNS. For more information, please visit http://www.medgenesis.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Michael Lincoln
Chief Financial Officer
MedGenesis Therapeutix Inc.
MichaelLincoln@medgenesis.com
(250) 386-3107

This news release contains certain forward looking statements that reflect the current views and/or expectations of the company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Show Less

 


MedGenesis Therapeutix Named One of Canada's Top 10 Life Science Companies

10-Dec-2007

MedGenesis Therapeutix Inc., a privately-held biopharmaceutical company, today announced that it has been recognized as one of Canada’s Top 10 Life Sciences Companies for 2008. MedGenesis was chosen by a group of distinguished venture capital investors based on the Company’s attractiveness as an exceptional investment in Canada. Show More

"We are honoured to have received this award," said Chairman and Chief Executive Officer, Dr. Erich Mohr. "It recognizes the value and potential of our platform technology and the significant achievements made by our company in the last year."

Winners of the Canada’s Top 10 Competition are chosen by an independent expert panel of Canadian and U.S. venture capitalists. Originally developed to promote the 10 most promising life science companies from across Canada to Canadian and international investors and partners, the competition has now expanded to showcase Canada's cleantech and technology sectors. Winning companies, working in partnership with OCRI, and the Canadian Consulates in Boston, New York City, San Diego and San Francisco, will participate in targeted investment forums in each city, providing them with an opportunity to meet with venture capital investors who have expressed an active interest in financing these companies.

For more information about the Canada's Top 10 Competition visit www.topcanadiancompanies.com.

About MedGenesis Therapeutix

MedGenesis Therapeutix Inc. is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life enhancing treatments to patients with serious Central Nervous System (CNS) Disease. MedGenesis is a worldwide leader in Convection Enhanced Delivery (CED), with a groundbreaking CED platform for local drug delivery inside the brain. For more information please visit http://www.medgenesis.com

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Show Less

 


MedGenesis Therapeutix Closes $3.2 Million Round of Financing

8-Nov-2006

MedGenesis Therapeutix Inc. ("MedGenesis") announced today that it has successfully raised $3.2 Million in private equity financing. The proceeds of the financing will be used to advance the clinical development of its lead therapeutic program and the filing of an IND to initiate human studies. Show More

"Investors were very receptive to the uniqueness of our business model and to the potential for success of our development programs," commented Dr. Erich Mohr, Chairman and Chief Executive Officer of MedGenesis. "This financing will enable MedGenesis to enter into phase I/II clinical trials with our lead drug candidate by the end of 2007 and provide us with sufficient funding to meet our other business objectives."

MedGenesis is a biopharmaceutical company focused on the development of therapeutics with established safety and efficacy profiles for the treatment of serious Central Nervous System (CNS) disease. The company utilizes Convection Enhanced Delivery as a method of direct and targeted delivery of molecules to the relevant area in the CNS. Key therapeutic focus areas include Neuro Oncology, Parkinson's Disease and Alzheimer's Disease.

FOR FURTHER INFORMATION PLEASE CONTACT:

Erich Mohr, Ph.D., R.Psych.
Chairman & Chief Executive Officer
MedGenesis Therapeutix Inc.
ErichMohr@medgenesis.com

Michael Lincoln
Chief Financial Officer
MedGenesis Therapeutix Inc.
MichaelLincoln@medgenesis.com

This news release contains certain forward looking statements that reflect the current views and/or expectations of the company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Show Less

 


MedGenesis Appoints Ken Newport to Board of Directors

31-Mar-2006

MedGenesis Therapeutix Inc. (MedGenesis) is pleased to announce that Mr. Ken Newport has been appointed to the Company's Board of Directors. Show More

Ken brings to the MedGenesis Board a wealth of experience in business development and corporate finance and we believe his leadership and complementary skill set will be an invaluable asset to the strategic direction and growth of our organization," said Dr. Erich Mohr, Chairman & Chief Executive Officer of MedGenesis.

Ken Newport is an entrepreneur and life sciences business executive and a chartered accountant. He was a co-founder and President of CroMedica Global Inc. Prior to its merger with PRA International, CroMedica had annual revenues of over $40 million with 600 employees in offices in 9 countries. From 2002-2005, Mr. Newport served as a Senior Vice President and Executive Committee member of PRA International. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He currently serves as the Chairman of the Ottawa Life Science Council.

"I am looking forward to contributing to the growth of MedGenesis. The business model is extremely unique and potentially allows for the Company to have products in the clinic as early as next year," said Mr. Newport.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Show Less

 


 

 

© MedGenesis Therapeutix Inc.